Swiss Private Equity & Corporate Finance Association
Schweizerische Vereinigung für Unternehmensfinanzierung
Association Suisse des Investisseurs en Capital et de Financement
E | D | F

Login



Forgotten password

Visit us on XING!

Visit us on LinkedIn!

CRISPR Therapeutics to raise funds

Swiss biopharmaceutical company CRISPR Therapeutics is to issue up to USD 100.00 million in new shares in a public offer. Goldman Sachs, Piper Jaffray and Barclays Capital have all been hired as bookrunners for the capital increase and Guggenheim Securities is a co-manager. The gene editing process developer will also offer the underwriters an overallotment option to buy an additional USD 15.00 million in shares. CRISPR Therapeutics performs research and development (R&D) into gene-based medicines to treat serious diseases and, as of 3rd January 2018, it had a market capitalisation of USD 1.03 billion. Source: Zephyr


Back to overview

Full Members
Contact

Swiss Private Equity & Corporate Finance Association
SECA
Grafenauweg 10
Postfach 4332
6304 Zug
Switzerland

Phone: +41 41 724 65 75